Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial

Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial

The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years. We carried out comprehensive molecular analysis in...

Full description

Bibliographic Details
Main Authors: Mackay, Alan, Burford, Anna, Molinari, Valeria, Jones, David T.W., Izquierdo, Elisa, Brouwer-Visser, Jurriaan, Giangaspero, Felice, Haberler, Christine, Pietsch, Torsten, Jacques, Thomas S., Figarella-Branger, Dominique, Rodriguez, Daniel, Morgan, Paul S., Raman, Pichai, Waanders, Angela J., Resnick, Adam C., Massimino, Maura, Garrè, Maria Luisa, Smith, Helen, Capper, David, Pfister, Stefan M., Würdinger, Thomas, Tam, Rachel, Garcia, Josep, Thakur, Meghna Das, Vassal, Gilles, Grill, Jacques, Jaspan, Tim, Varlet, Pascale, Jones, Chris
Format: Article
Language:English
Published: Elsevier 2018
Subjects:
Immune; CD8; MAPK; Hypermutator; H3F3A; Pediatric high-grade glioma
Online Access:https://eprints.nottingham.ac.uk/51975/

Internet

https://eprints.nottingham.ac.uk/51975/

Similar Items